ClinicalTrials.gg
RecruitingNCT06907836ATTR-CAUpdated Apr 2, 2025

Description of a Retrospective Cohort of Patients With Transthyretin Cardiac Amyloidosis (ATTR-CA) in Internal Medicine

An observational study in Cardiac Amyloidosis, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by University Hospital, Strasbourg, France · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Amyloid Neuropathies, Familial with a site in France — 15 open to participants now, 16 under way, 1 of them phase 3. Amyloid Neuropathies, Familial · France.

Planned enrollment
10th of 12
30 · median 175
Started
2024
with 3 others
Observational
12 of 35
9 open now
Primary completion
2025-12
later than 3 of 15 live
Registered
32nd of 35
by date

Among the 35 studies in Amyloid Neuropathies, Familial with a site in France, this one is the 10th largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2024, is one of 12 observational ones, reaches primary completion later than 3 of the 15 other live ones, and was the 32nd registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

15 of the 35 studies in Amyloid Neuropathies, Familial with a site in France are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Amyloid Neuropathies, Familial with a site in France, or all of them as a file.
02

Study summary

In 2024, the prevalence of TTR cardiac amyloidosis is difficult to determine precisely. Indeed, the disease has long been underdiagnosed due to a lack of effective treatment and non-invasive diagnostic methods. The prevalence of ATTRwt is estimated at 155 to 191 cases per million person-years, with an incidence of 36 cases per million person-years. Both incidence and prevalence increase with age.

The most common presentation of TTR cardiac amyloidosis is heart failure with preserved ventricular ejection fraction (LVEF).

The natural history of TTR cardiac amyloidosis is progression to restrictive heart disease with all the complications described above.

The median time between diagnosis and the first cardiac symptoms was 39 months. Currently, the median survival in France is approximately 3.5 years, but survival appears to be improving, with a mortality rate of 73.5% at 30 months between 2002 and 2006, compared to 15% at 60 months between 2017 and 2022.

The number of patients diagnosed with TTR cardiac amyloidosis appears to be increasing. The overwhelming majority of available data concerns patients treated in cardiology. However, the issue of TTR cardiac amyloidosis concerns all specialists caring for patients with heart failure, particularly in internal medicine due to the high number of admissions from emergency departments, with a significant proportion of patients suffering from cardiac decompensation.

03

Conditions studied

  • Cardiac Amyloidosis

Keywords

  • Cardiac Amyloidosis
  • Internal medicine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Sujet majeur (≥18 ans) avec un diagnostic d'amylose à TTR

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sujet majeur (≥18 ans)
  • Diagnostic d'amylose à TTR suite à une hospitalisation en médecine interne aux HUS entre 01/01/2013 au 31/12/2023.

Exclusion criteria

Exclusion Criteria:

  • Subject (and/or their legal representative, if applicable) who has expressed their opposition to the reuse of their data for scientific research purposes.
  • Type of amyloidosis other than ATTR after review of the medical record (immunological assessment, imaging assessment, expert report).
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
30 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Describe the number of cases of transthyretin (TTR) cardiac amyloidosis referred to internal medicine between 2013 and 2023.

    Time frame: Up to 10 years

07

Study locations

1 of 1 sites recruiting
  • Service de Médecine Interne - CHU de Strasbourg - France
    Strasbourg, 67091, France
    Recruiting
    • Emmanuel ANDRES, MD, PhD · Contactemmanuel.andres@chru-strasbourg.fr · 33 3 88 12 71 33
    • Emmanuel ANDRES, MD, PhD · Principal investigator
    • Xavier JANNOT, MD · Sub investigator
    • Nöel LORENZO, MD · Sub investigator
    • Clara BARHOUMI, Statistician · Sub investigator
    • François SEVERAC, Statistician · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Dec 2025, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2025
First posted
Apr 2, 2025
StartActual
Apr 22, 2024
Primary completionEst.
Dec 22, 2025
CompletionEst.
Dec 22, 2025
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06907836
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
Apr 22, 2024
Primary completion
Dec 22, 2025 (estimated)
Completion
Dec 22, 2025 (estimated)
Last update
Apr 2, 2025

Study contacts

Emmanuel ANDRES, MD, PhD
Contact
emmanuel.andres@chru-strasbourg.fr
33 3 88 12 71 33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion